Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 46

Related Articles by Review for PubMed (Select 21287572)

1.

Targeted drug delivery and penetration into solid tumors.

Corti A, Pastorino F, Curnis F, Arap W, Ponzoni M, Pasqualini R.

Med Res Rev. 2012 Sep;32(5):1078-91. doi: 10.1002/med.20238. Epub 2011 Feb 1. Review.

PMID:
21287572
2.

NGR-based strategies for targeting delivery of chemotherapeutics to tumor vasculature.

Zou M, Zhang L, Xie Y, Xu W.

Anticancer Agents Med Chem. 2012 Mar;12(3):239-46. Review.

PMID:
22263803
3.

Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.

Corti A, Ponzoni M.

Ann N Y Acad Sci. 2004 Dec;1028:104-12. Review.

PMID:
15650236
4.

Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.

Corti A, Curnis F, Rossoni G, Marcucci F, Gregorc V.

BioDrugs. 2013 Dec;27(6):591-603. doi: 10.1007/s40259-013-0048-z. Review.

5.

Development of NGR-based anti-cancer agents for targeted therapeutics and imaging.

Wang RE, Niu Y, Wu H, Hu Y, Cai J.

Anticancer Agents Med Chem. 2012 Jan;12(1):76-86. Review.

PMID:
22023047
6.

Tumor vasculature targeting through NGR peptide-based drug delivery systems.

Corti A, Curnis F.

Curr Pharm Biotechnol. 2011 Aug;12(8):1128-34. Review.

PMID:
21470145
7.

Clinical studies with targeted toxins in malignant glioma.

Rainov NG, Söling A.

Rev Recent Clin Trials. 2006 May;1(2):119-31. Review.

PMID:
18473963
8.

Novel advances in drug delivery to brain cancer.

Lesniak MS.

Technol Cancer Res Treat. 2005 Aug;4(4):417-28. Review.

PMID:
16029060
9.

Peptides for cell-selective drug delivery.

Svensen N, Walton JG, Bradley M.

Trends Pharmacol Sci. 2012 Apr;33(4):186-92. doi: 10.1016/j.tips.2012.02.002. Epub 2012 Mar 15. Review.

PMID:
22424670
10.

Drug delivery and transport to solid tumors.

Jang SH, Wientjes MG, Lu D, Au JL.

Pharm Res. 2003 Sep;20(9):1337-50. Review.

PMID:
14567626
11.

Vascular targeting agents as cancer therapeutics.

Thorpe PE.

Clin Cancer Res. 2004 Jan 15;10(2):415-27. Review.

12.

Solid tumor therapy: manipulation of the vasculature with TNF.

ten Hagen TL, Eggermont AM.

Technol Cancer Res Treat. 2003 Jun;2(3):195-203. Review.

PMID:
12779350
13.

Efficiency of recombinant human TNF in human cancer therapy.

Lejeune FJ, Liénard D, Matter M, Rüegg C.

Cancer Immun. 2006 Mar 22;6:6. Review.

14.

The neovasculature homing motif NGR: more than meets the eye.

Corti A, Curnis F, Arap W, Pasqualini R.

Blood. 2008 Oct 1;112(7):2628-35. doi: 10.1182/blood-2008-04-150862. Epub 2008 Jun 23. Review.

15.

Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.

ten Hagen TL, Seynhaeve AL, Eggermont AM.

Immunol Rev. 2008 Apr;222:299-315. doi: 10.1111/j.1600-065X.2008.00619.x. Review.

PMID:
18364010
16.

Modulation of death receptor pathways in oncology.

de Vries EG, Timmer T, Mulder NH, van Geelen CM, van der Graaf WT, Spierings DC, de Hooge MN, Gietema JA, de Jong S.

Drugs Today (Barc). 2003;39 Suppl C:95-109. Review.

PMID:
14988748
17.

Drug development for cancer chemoprevention: focus on molecular targets.

Johnson KA, Brown PH.

Semin Oncol. 2010 Aug;37(4):345-58. doi: 10.1053/j.seminoncol.2010.05.012. Review.

PMID:
20816505
18.

Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery.

Li ZJ, Cho CH.

J Transl Med. 2012 Sep 19;10 Suppl 1:S1. doi: 10.1186/1479-5876-10-S1-S1. Epub 2012 Sep 19. Review.

19.

Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs.

Dubowchik GM, Walker MA.

Pharmacol Ther. 1999 Aug;83(2):67-123. Review.

PMID:
10511457
20.

Molecular targeting of angiogenesis.

Alessi P, Ebbinghaus C, Neri D.

Biochim Biophys Acta. 2004 Mar 4;1654(1):39-49. Review.

PMID:
14984766
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk